| # Patients Randomized |
Study Groups |
Stratification | Significance Demonstrated |
% Change Identified in Trial |
|---|---|---|---|---|
| 746 | Imatinib 400 mg daily n = 345 Imatinib 400 mg twice daily n = 349 |
By Zubrod performance status (0–2 vs. 3) and by disease status (measurable vs. unmeasurable) | No significant differences in progression-free survival or overall survival | p = ns |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.